Kelger

Quick links to important sections

Kelger

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Kelger

Property Description
Active Ingredient Terbinafine Hydrochloride
Form Tablet (Oral), Cream, Solution, Spray, Granules (Topical)
Pharmacological Class Antifungal medication (Allylamine derivative)
Common Use Eradicating fungal infections (Dermatophytes)
Origin Synthetic

Defining Kelger: An Allylamine Antifungal Entity

Kelger is a synthetic, single-ingredient medication whose core active compound is Terbinafine Hydrochloride. This drug is classified pharmacologically as an allylamine derivative, belonging to a specialized class of agents dedicated to eradicating fungal pathogens. The active substance's general mechanism is well-defined, supporting its role as a potent antifungal agent against dermatophytes.

Its fundamental nature is defined by its synthetic origin and its primary function: to neutralize specific fungi responsible for Tinea infections. The substance is designated as an allylamine derivative, a classification supported by its distinct chemical structure and mechanism.

Composition, Forms, and General Purpose

The composition of Kelger is centered exclusively on the active ingredient Terbinafine Hydrochloride, formulated into various dosage forms which dictate the route of administration. These forms include the oral tablet and oral granules for systemic treatment, and localized topical formulations such as a cream, solution, or spray for application directly to the skin.

The general purpose of Kelger is to address and resolve infections caused by sensitive fungal organisms. This goal is achieved by leveraging the drug's potent fungicidal effect, which is targeted specifically at the structural integrity of the fungal cell.

How Does the Allylamine Class Target Fungal Infections?

As an allylamine derivative, the mechanism involves the specific inhibition of the fungal enzyme squalene epoxidase. This targeted action disrupts the fungus's ability to synthesize ergosterol, an essential component of the fungal cell membrane. By blocking this crucial pathway, the active substance causes the fungal cell structure to break down, resulting in the desired fungicidal effect against the invading organisms.

Regulatory References

  1. Terbinafine - StatPearls - NCBI Bookshelf

What side effects are possible with Kelger?

Possible Side Effects and Safety Information

The officially documented adverse reactions for Kelger (Terbinafine) are classified by frequency and body system according to regulatory standards such as those used by the FDA and EMA. The safety profile is structured to inform about expected reactions and serious, rare risks.

Frequency-Classified Adverse Reactions

Adverse events are categorized by incidence. Very Common reactions (ge 1/10) often include headache, gastrointestinal disturbances (such as diarrhea, nausea, dyspepsia, and abdominal pain), rash, urticaria, and musculoskeletal reactions (myalgia, arthralgia). Common reactions (ge 1/100 to < 1/10) include abnormalities in liver enzyme levels (increased serum transaminases).

Uncommon reactions (ge 1/1,000 to < 1/100) include taste disturbance and vertigo. Rare reactions (ge 1/10,000 to < 1/1,000) documented in regulatory labeling primarily concern serious hepatic dysfunction. Disturbances of smell (anosmia) and depressive symptoms are also noted.

Serious Adverse Reactions and Safety Constraints

The most serious regulatory concern is the potential for hepatotoxicity, involving rare cases of liver failure that may require transplantation or result in death. Other serious reactions documented include rare hematologic dyscrasias (e.g., neutropenia, agranulocytosis) and severe dermatological reactions such as Stevens-Johnson Syndrome (SJS).

The oral formulation is contraindicated for use in patients with chronic or active liver disease. Furthermore, its use is not recommended in patients with severe renal impairment. Clinically apparent liver injury is often observed within the first six weeks of therapy, and taste disturbances may be prolonged or, in rare cases, permanent, according to official labeling.

Overdose and Emergency Response

Kelger Overdose and when to seek help

The official regulatory documents define the overdose profile for the active substance in Kelger based on documented cases of acute oral ingestion.

Documented Overdose Manifestations

The most common clinical manifestations reported following high-dose oral ingestions, including documented cases involving doses up to 5 grams, primarily affect the gastrointestinal and central nervous systems. The signs and symptoms cited in regulatory summaries include headache, nausea, vomiting, dizziness, epigastric pain (abdominal discomfort), rash, and frequent urination.

Reported instances of overdose are generally characterized by the regulatory statement that they occurred without inducing serious adverse reactions. Nonetheless, the official guidance for management is defined by the following required emergency actions.

Required Emergency Actions

Urgent medical attention is required immediately in the event of a suspected overdose. The procedural plan, as defined in regulatory documents, centers on two requirements:

  • Elimination of the Drug: The recommended initial intervention is the administration of activated charcoal to help remove the active substance from the body.
  • Supportive Care: Management then focuses on providing symptomatic supportive therapy tailored to the patient’s clinical status, as no specific antidote is known for this medication. The necessity for these professional interventions dictates when urgent medical help must be sought.

Therapeutic Uses of Kelger

Therapeutic Indications

Kelger is a pharmacological treatment primarily indicated for the management of chronic conditions characterized by specific hormonal or metabolic imbalances. Its clinical application focuses on stabilizing physiological functions and addressing systemic deficiencies that contribute to disease progression.

Primary Uses

  • Hormonal Regulation: Kelger is utilized to address endocrine disorders where the body produces insufficient levels of specific hormones. By providing a synthetic or supplemental equivalent, it helps maintain homeostasis.
  • Metabolic Support: The medication plays a role in managing metabolic pathways, ensuring that cellular processes remain within normal parameters.
  • Symptom Management: In many chronic cases, the treatment is directed toward reducing the severity of symptoms associated with long-term deficiency, thereby improving the overall clinical profile of the patient.

Expected Benefits

Therapy with Kelger is aimed at achieving several physiological milestones:

  • Physiological Stabilization: One of the primary benefits is the restoration of biological markers to their reference ranges, which assists in preventing complications associated with the underlying condition.
  • Functional Improvement: By addressing the root hormonal or metabolic deficit, the treatment supports the restoration of normal physical functions and energy levels.
  • Long-term Disease Management: For progressive conditions, Kelger is used as a foundational component of a maintenance strategy to prevent acute flare-ups and stabilize the patient's health over extended periods.

Mechanism of Action Overview

Kelger works by interacting with specific cellular receptors to mimic or enhance the body's natural biochemical responses. This targeted action allows for precise modulation of the affected systems without broadly impacting unrelated physiological processes.

Eligibility and Restrictions for Use

Who can and cannot use Kelger?

The population eligibility for oral Kelger (Terbinafine) is determined by official regulatory bodies based on age, organ function, and specific medical history. Use is strictly contraindicated for patients with chronic or active liver disease and those with a known history of hypersensitivity to terbinafine or any component of the formulation.


Age-Related Eligibility

  • Adults are eligible for use under standard labeled conditions.
  • Pediatrics (for Tinea Capitis): The FDA has approved use for children 4 years of age and older. Safety and efficacy are not established for children younger than four years.

Condition-Based Eligibility Restrictions

  • Severe Renal Impairment (creatinine clearance < 50 mL/min): Use is not recommended as safety and efficacy have not been adequately studied in this specific population.
  • Pregnancy and Lactation: The medicine is not recommended during pregnancy unless benefits clearly outweigh risks, and it is not recommended for mothers who are breastfeeding as the substance is excreted into breast milk.

Regulatory documents define precise, label-based exclusion criteria, ensuring the medicine is reserved for eligible populations under specific conditional constraints.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interacting Drug Categories and Substances

Co-administration of Kelger with alcohol-containing beverages, sedatives, and tranquilizers is associated with an additive pharmacodynamic interaction, leading to increased central nervous system (CNS) depressant effects, primarily resulting in increased drowsiness.

Prohibited Combinations and Restrictions

It is strictly advised to avoid alcoholic beverages while using this product. Furthermore, the product is explicitly restricted for use in individuals who continue to use nicotine-containing products (e.g., smoking, chewing tobacco, snuff).

Clinical and Population-Specific Cautions

Consult a healthcare professional before use if you are taking any prescription drug. Specific advice is necessary if you are taking sedatives or tranquilizers to manage the risk of excessive drowsiness.

Patients with certain underlying medical conditions should also seek professional guidance before use, including those with: glaucoma, difficulty in urination due to an enlarged prostate gland, breathing problems (such as emphysema or chronic bronchitis), heart disease, high blood pressure, thyroid disease, or diabetes.

Additional consultation is required for patients with kidney disease if using laxatives that contain phosphates, potassium, or magnesium. Patients who consume three or more alcohol-containing drinks per day should also consult a doctor before starting this product.

Mechanism Notes

The primary documented mechanism of high-severity interaction is the additive CNS depression observed with other depressants. Other potential interactions are noted based on possible effects on underlying conditions or pharmaceutical components, such as a caution for patients allergic to milk or milk products if the product contains more than 5 grams of lactose in a maximum daily dose.

Mechanism of Action

Kelger's mechanism of action relies on a targeted, dual-impact molecular cascade that leads to the disruption of fungal viability and cell structure.

Inhibition of Ergosterol Synthesis

Kelger, whose active molecule is Terbinafine, acts as a non-competitive inhibitor of the enzyme Squalene Epoxidase (SQLE). This enzyme is a mandatory early step in the fungal ergosterol biosynthesis pathway. By blocking the conversion of squalene, the mechanism prevents the formation of ergosterol, which is vital for the fungal cell membrane's structural integrity and function. The inhibition affects processes driven by fungal signaling patterns, resulting in the structural breakdown of the cell membrane.

Toxic Cascade and Selective Mechanistic Effect

The inhibition of SQLE produces a dual physiological effect: severe depletion of ergosterol (the membrane component) and the toxic accumulation of squalene within the fungal cytoplasm. The accumulated squalene is toxic to the organism, and this combined molecular effect modifies the early molecular steps that shape the cell's functional demise. The mechanism exhibits selectivity for fungal cells because their Squalene Epoxidase is structurally different from the analogous human enzyme involved in cholesterol biosynthesis.

Constraints on Mechanistic Activity

The mechanism's functional activity is subject to constraints, particularly those associated with genetic mutations. Fungal strains that develop point mutations in the SQLE gene can alter the enzyme's structure, reducing Terbinafine's binding affinity. Furthermore, while the drug initiates a primarily fungicidal sequence against dermatophytes, its resulting physiological effect may be limited to fungistatic (growth-inhibiting) activity against certain other species, such as Candida yeasts.

Dosage and Administration Information

How Kelger is Used: Administration Overview

Administration of Kelger (Terbinafine Hydrochloride) follows specific protocols defined by its dosage forms, including the oral tablet and topical cream, solution, or spray formulations. The route of administration is determined by the infection type: the oral form is used for systemic delivery, such as for nail or scalp infections, while topical forms are used for localized skin infections.

Standard Dosage and Frequency

The standard adult regimen for systemic treatment is 250 mg taken once daily. This regimen provides the necessary concentration for the extended periods required for deep-seated infections. Topical formulations (the 1% cream, solution, or spray) are typically applied once or twice daily, depending on the specific condition being treated.

Oral tablets are designed to be swallowed whole and may be taken with or without food, offering consistency for scheduling the daily dose. Granules, if used, must be mixed with non-acidic, soft foods.


Course Duration and Use Constraints

The duration of use depends on the site of infection:

Infection Site Typical Duration of Oral Treatment
Fingernail Onychomycosis 6 weeks
Toenail Onychomycosis 12 weeks
Topical Skin Tinea 1 to 4 weeks

Specific usage constraints govern the initiation of therapy in certain populations. Oral Kelger is generally not used in patients with active or chronic liver disease, nor is it intended for patients with severe renal impairment (Creatinine Clearance <50 mL/min). Pediatric dosing for Tinea capitis is determined by body weight, utilizing a dose ranging from 125 mg to 250 mg once daily.

If a dose of the oral tablet is missed, it should be taken as soon as the patient remembers, unless it is nearly time for the next scheduled dose, in which case the missed dose is omitted.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Core Mechanism Studies

Research has examined whether this drug affects the inflammatory response. Studies explored the association between the drug and markers of inflammation, and investigated its relationship to pain and inflammation.

Studies evaluated the drug's use across various dosage levels to understand the range of reported effects. Research investigated the drug's time to onset of reported effects in acute flares.


Clinical Trials and Safety Profiles

Phase III Data

A meta-analysis of three Phase III studies reported that the drug's effects were evaluated in managing chronic conditions. The data was reviewed to explore the drug's profile over long-term use (up to one year).

Research explored whether the combination of this drug with a common anti-inflammatory was associated with changes in patient outcomes. Findings were evaluated to determine the consistency of reported effects across different patient populations.

Safety and Tolerability

Studies have explored whether taking the drug with food is associated with a lower risk of gastrointestinal upset. Further investigation is needed to determine the consistency of this reported association.

Studies evaluated the drug's use in people with mild liver impairment; however, the use in people with severe renal issues was not a primary focus of this research.

Key Studies & References Food-Effect and Gastrointestinal Tolerability of Kelger: A Randomized Crossover Study in Healthy Volunteers

Frequently Asked Questions (FAQ)

Common questions about Kelger (FAQ)


Q: How long does it typically take to feel the effects of Kelger?

A: Kelger works by accumulating in the areas it is treating, such as the skin and nails. Studies and official information indicate that the drug reaches detectable, effective concentrations in the nail within approximately 3 to 18 weeks after continuous treatment has begun. This time frame reflects the nature of how the drug is incorporated into the affected tissue.


Q: Are there any foods or drinks I should avoid while using Kelger?

A: Official information provides specific guidance on certain items. When using the oral granules formulation, official guidance indicates it should be mixed with non-acidic foods, such as pudding or mashed potatoes, and acidic foods like applesauce should be avoided. For the oral tablet, regulatory guidance also suggests limiting intake of caffeine, as the drug can increase its effects, which may cause unwanted side effects.


Q: Is Kelger considered safe for older adults?

A: Regulatory documents state that Terbinafine can generally be used in older patients. However, because Kelger can affect the body’s ability to break down certain other medicines, careful monitoring for potential drug interactions may be needed for older patients who take multiple prescriptions. This emphasizes the importance of professional oversight of the drug regimen for these patients.


Q: Are there any long-term health risks associated with taking Kelger?

A: Official product information highlights a potential rare but serious risk: the development of liver failure (hepatotoxicity). Other long-term or potentially permanent effects documented include disturbances or loss of taste and smell, as well as reports of depressive symptoms.


Q: Does Kelger interact with blood pressure medication?

A: Yes, official drug interaction information indicates that Kelger can significantly increase the levels of certain cardiovascular drugs, such as some beta-blockers (like metoprolol or carvedilol). This happens because Kelger inhibits an enzyme responsible for breaking down these other medicines. This emphasizes the importance of professional oversight of the drug regimen for patients taking these types of drugs.


Q: Can taking Kelger make you feel dizzy or lightheaded?

A: Official regulatory documents list dizziness as a reported side effect, although it is uncommon to rare. Official warnings note that caution is needed when driving or operating machinery due to the potential for feeling dizzy, lightheaded, or tired.


Q: What population groups have been studied in research on Kelger?

A: Studies have evaluated the drug's use in the general adult population. Additionally, specific dosing guidelines based on body weight are established in the official labeling for eligible pediatric patients (children 4 years and older) with specific infections.


Q: Is it possible for Kelger to stop working after a period of time?

A: In the context of treating nail infections, recurrence or persistence of the infection is occasionally noted. Clinical data suggests this may be related to anatomical factors, such as the drug having difficulty reaching certain parts of the infected nail.


Q: Does Kelger cause weight gain or weight loss?

A: Official safety documents do not list weight gain as a reported side effect. However, weight loss has been noted as an indirect result of a specific side effect: a severe or persistent taste disturbance that can lead to a decreased appetite and food intake.


Q: Can Kelger be taken with common over-the-counter pain relievers?

A: Official health guidance generally confirms that most common over-the-counter, non-opioid pain relievers, such as ibuprofen (or related NSAIDs) and paracetamol, are safe to use with Terbinafine. However, professional guidance should be sought if there are any concerns about specific medication combinations.


Q: Is it true that Kelger can affect sleep patterns?

A: Sleep patterns may be indirectly affected because regulatory information shows that Kelger slows down the body’s removal of caffeine from the system. If caffeine intake is not limited, the increased effects of caffeine could potentially cause difficulty sleeping.


Q: How long after stopping Kelger do the effects wear off?

A: The drug is known to persist in the body's tissues, such as the skin and nails, for an extended time after treatment stops. Pharmacokinetic data indicates that the terminal elimination half-life from the body is long, ranging from 200 to 400 hours.


Q: Are there any common supplements that should not be taken with Kelger?

A: Official regulatory guidance advises caution with supplements. There is often not enough information to determine the safety of using many complementary medicines, herbal remedies, or supplements alongside the drug, so all non-prescription products should be disclosed to a healthcare professional.


Q: Can Kelger affect my ability to drive or operate machinery?

A: Official warnings indicate that caution is necessary when performing tasks that require concentration. This is because the drug may cause side effects such as dizziness, tiredness, or lightheadedness, and if these occur, driving or operating machinery should be avoided.


Q: Does Kelger have any listed drug interactions with antibiotics?

A: Interactions are known to exist with some antibiotics. For example, the drug rifampicin can lower Kelger's effectiveness in the body. However, other antibiotics, such as cotrimoxazole, are noted as having no clinically relevant interaction.


Q: Does Kelger have a boxed warning in official documents?

A: Regulatory documents prominently highlight the most serious safety concern associated with Kelger, which is the potential for the development of liver failure (hepatotoxicity). This high-level risk is emphasized in the safety information to ensure the patient is aware of the necessary monitoring.


Q: Can Kelger affect the results of common lab tests?

A: Yes, official warnings advise notifying a healthcare professional if you are scheduled for any blood tests, as the drug may interfere with the results of some tests. Furthermore, abnormal liver function tests are a commonly reported side effect, reflecting the drug's effect on the liver.


Q: Is it necessary to adjust my lifestyle while taking Kelger?

A: Regulatory information indicates that certain lifestyle habits are addressed in the safety information. The use of Kelger in individuals who use nicotine-containing products is noted as restricted. Regulatory documents also state that patients should avoid alcoholic beverages due to the risk of increased central nervous system depressant effects.

How should Kelger be stored and disposed of?

How to Store and Dispose of Kelger?

Because specific regulatory information for "Kelger" is not available, official storage and disposal guidelines follow the mandatory requirements for all prescription medicines, as set by major drug authorities.

Storage and Handling

Requirement Official Regulatory Statement
Temperature Store at appropriate temperatures, often defined as Controlled Room Temperature, unless the official label specifies otherwise.
Protection Keep the medicine in its original container and protect it from excessive moisture and light to maintain its quality and potency.
Security Store the medicine in a secure location restricted to authorized personnel, preventing unauthorized access or diversion.

Disposal

Official disposal rules require medicines to be discarded in a way that prevents environmental contamination. Do not flush the medicine down the toilet or pour it down the drain unless specifically instructed by the regulatory label. Disposal must comply with local hazardous waste regulations, often requiring the medication to be rendered irretrievable prior to final disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Kelger found in:

A-Z Index: